Literature DB >> 28405703

Metabolic syndrome contributes to renal injury mediated by hyperoxaluria in a murine model of nephrolithiasis.

Javier Sáenz-Medina1, E Jorge2, C Corbacho3, M Santos4, A Sánchez5, P Soblechero2, E Virumbrales2, E Ramil6, M J Coronado7, I Castillón8, D Prieto9, J Carballido8.   

Abstract

Metabolic syndrome (MS) individuals have a higher risk of developing chronic kidney disease through unclear pathogenic mechanisms. MS has been also related with higher nephrolithiasis prevalence. To establish the influence of MS on renal function, we designed a murine model of combined metabolic syndrome and hyperoxaluria. Four groups of male Sprague-Dawley rats were established: (1) control group (n = 10) fed with standard chow; (2) stone former group (SF) (n = 10) fed with standard chow plus 0.75% ethylene glycol administered in the drinking water; (3) metabolic syndrome group (MS) (n = 10), fed with 60% fructose diet; (4) metabolic syndrome + stone former group (MS + SF) (n = 10), 60% fructose diet and 0.75% EG in the drinking water. MS group showed a significant injury to renal function when hyperoxaluria was induced. It was demonstrated by a significant decrease of creatinine clearance (p < 0.001), with higher tubular damage (34.3%, CI 95% 23.9-44.7, p < 0.001), produced by deposition of crystals, and increased tubular synthesis of osteopontin as a response to tubular damage. Induction of hyperoxaluria in rats with MS causes severe morphological alterations with a significant impairment of renal function. This impairment is not produced in rats without MS. Therefore, this model can be useful for the study of the influence of MS in stone formation.

Entities:  

Keywords:  Hyperoxaluria; Metabolic syndrome; Oxidative stress; Renal stone

Mesh:

Substances:

Year:  2017        PMID: 28405703     DOI: 10.1007/s00240-017-0979-9

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  21 in total

1.  Calcium oxalate crystal deposition in metabolic syndrome model rat kidneys.

Authors:  Masanori Okamoto; Yasuo Kohjimoto; Akinori Iba; Fumie Saji; Isao Hara; Takashi Shigematsu
Journal:  Int J Urol       Date:  2010-12       Impact factor: 3.369

2.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus
Journal:  Crit Pathw Cardiol       Date:  2005-12

Review 3.  Renal lipid metabolism and lipotoxicity.

Authors:  Ion Alexandru Bobulescu
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-07       Impact factor: 2.894

4.  [Metabolic syndrome: prevalence, risk factors and mortality in a French population of 62 000 subjects].

Authors:  Louis Guize; Frédérique Thomas; Bruno Pannier; Kathy Bean; Nicolas Danchin; Athanase Bénétos
Journal:  Bull Acad Natl Med       Date:  2006-03       Impact factor: 0.144

Review 5.  Lipotoxic diseases.

Authors:  Roger H Unger
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

Review 6.  Animal models of kidney stone formation: an analysis.

Authors:  S R Khan
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 7.  Recent advances in metabolic syndrome and cardiovascular disease.

Authors:  Louis Guize; Bruno Pannier; Frédérique Thomas; Kathy Bean; Bertrand Jégo; Athanase Benetos
Journal:  Arch Cardiovasc Dis       Date:  2008-09-25       Impact factor: 2.340

8.  Uric acid saturation in calcium nephrolithiasis.

Authors:  F L Coe; A L Strauss; V Tembe; S Le Dun
Journal:  Kidney Int       Date:  1980-05       Impact factor: 10.612

Review 9.  Effects of citrate on the different phases of calcium oxalate crystallization.

Authors:  H G Tiselius; C Berg; A M Fornander; M A Nilsson
Journal:  Scanning Microsc       Date:  1993-03

10.  Association between metabolic syndrome and nephrolithiasis in an inpatient population in southern Italy: role of gender, hypertension and abdominal obesity.

Authors:  Domenico Rendina; Giuseppe Mossetti; Gianpaolo De Filippo; Domenico Benvenuto; Carmen Liliana Vivona; Alessia Imbroinise; Giorgia Zampa; Salvatore Ricchio; Pasquale Strazzullo
Journal:  Nephrol Dial Transplant       Date:  2008-10-03       Impact factor: 5.992

View more
  5 in total

Review 1.  Urinary oxalate as a potential mediator of kidney disease in diabetes mellitus and obesity.

Authors:  Orhan Efe; Ashish Verma; Sushrut S Waikar
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

2.  A pilot dynamic analysis of formative factors of nephrolithiasis related to metabolic syndrome: evidence in a rat model.

Authors:  Qiqi He; Yangguo Tang; Yuzhuo Li; Fei Wang; Junsheng Bao; Sanjay Gupta
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

3.  Metabolomic analysis reveals a protective effect of Fu-Fang-Jin-Qian-Chao herbal granules on oxalate-induced kidney injury.

Authors:  Wei Chen; Wen-Rui Liu; Jie-Bin Hou; Jia-Rong Ding; Zhong-Jiang Peng; Song-Yan Gao; Xin Dong; Jun-Hua Ma; Qi-Shan Lin; Jian-Rao Lu; Zhi-Yong Guo
Journal:  Biosci Rep       Date:  2019-02-22       Impact factor: 3.840

4.  Hyperoxaluria Induces Endothelial Dysfunction in Preglomerular Arteries: Involvement of Oxidative Stress.

Authors:  Javier Saenz-Medina; Mercedes Muñoz; Claudia Rodriguez; Cristina Contreras; Ana Sánchez; María José Coronado; Elvira Ramil; Martin Santos; Joaquín Carballido; Dolores Prieto
Journal:  Cells       Date:  2022-07-27       Impact factor: 7.666

5.  Urolithiasis Develops Endothelial Dysfunction as a Clinical Feature.

Authors:  Javier Sáenz-Medina; María Martinez; Silvia Rosado; Manuel Durán; Dolores Prieto; Joaquín Carballido
Journal:  Antioxidants (Basel)       Date:  2021-05-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.